Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hospital study aims to find best way to monitor blood thinner dosing

NCT ID NCT06329921

Disease control Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 21, 2026 · Updated 4 times

Summary

This study compares two methods for monitoring the blood thinner heparin in hospitalized patients with blood clots. One method uses a standard clotting test (PTT), while the other uses a newer test (anti-Xa). The goal is to see which method helps patients reach the right blood thinner level faster. About 700 adults at Vanderbilt University Hospital will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
unfractionated heparin
What this could lead to
If successful, this could show which monitoring method is better for quickly getting blood thinner levels right, potentially improving treatment for blood clots.
What could go wrong
This is a pragmatic trial comparing existing methods, not testing a new drug. Results may not apply to all hospitals or patients, and the study is observational in nature.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

700 people

The number who actually took part.

Started

Jun 2024

Finished

Sep 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients at Vanderbilt University Hospital age 18 years and older who are admitted as observation or inpatients for whom intravenous unfractionated heparin (monitored via the PTT nurse-managed protocol) is ordered. * Baseline PTT value is ≥0 and ≤ 36.0 seconds * Baseline heparin level anti-Xa assay value is ≥0 and ≤0.3 Exclusion Criteria: * Indication for anticoagulation is extracorporeal membrane oxygenation or cerebrovascular ischemic event. * Provider determines patient is not appropriate for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood clot are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

thrombotic disease venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood clot Thrombosis

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.